NCT01780051View on ClinicalTrials.gov

A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Repaglinide/Metformin combination, Repaglinide, Metformin

"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."

DRUG

Repaglinide/Metformin combination, Repaglinide, Metformin

"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."

Trial Locations (1)

Unknown

Chounbuk National University Hospital, Jeonju

All Listed Sponsors
lead

Dalim BioTech Co., Ltd.

INDUSTRY

NCT01780051 - A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components | Biotech Hunter | Biotech Hunter